ギラン・バレ症候群
Nortina Shahrizaila1, Helmar C Lehmann2, Satoshi Kuwabara3
1Neurology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Lancet (London, England)
|March 1, 2021
まとめ
Guillain-Barré症候群は,麻痺の原因であり,COVID-19のような感染症と関連しています. 免疫療法は多くの人々を助けますが 障害や死亡を減らすために 世界的に改善された治療法と新しい治療法が必要です
科学分野:
- 神経科学
- 免疫学
- 感染症
背景:
- グイラン・バレー症候群は 世界的に急性軟性麻痺の主な原因です
- 肺炎は上部呼吸器系感染症を含む感染症に続いて発症することが多く,カンピロバクター・ジェジュニ,ジカウイルス,SARS-CoV-2と関連している.
- 病原性には,自己抗体媒介の免疫反応があり,分子模倣によって引き起こされる可能性があります.
研究 の 目的:
- グイラン・バレー症候群に関する現在の理解を レビューする
- 診断上の課題と 既存の診断基準の限界を強調する
- 治療結果や 地域差異や 将来の治療方向について
主な方法:
- ギラン・バリ症候群に関する既存の文献のレビュー
- 国際ギラン・バレー症候群調査のデータ分析
- 新しい治療法の進行中の臨床試験の検討
主要な成果:
- 古典的なギラン・バリ症候群の診断は一般的には簡単ですが,変異は見逃されることがあります.
- 免疫療法はほとんどの患者にとって有効ですが,重大な障害や死亡率は持続しています.
- 特に低所得国における 治療へのアクセスにおける 地域的差異が特定されました
結論:
- グイラン・バレー症候群の免疫療法への世界的なアクセスを改善することは極めて重要です.
- 神経損傷を制限する病気を修正する治療法の開発が必要である.
- 進行中の研究と臨床試験は 補完剤阻害剤を含む 治療法と理解を前進させると約束しています
さらに関連する動画
09:29Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
11.8K
08:16Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
Published on: March 4, 2014
32.8K
関連する概念動画
Myasthenia Gravis: Overview and Treatment
2.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.4K
Myasthenia Gravis: Diagnostic Tests
1.6K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.6K
Disorders of the Skeletal Muscle
1.4K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.4K
Chemical Synapses
10.5K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
10.5K
Chemical Synapses
3.8K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
3.8K
Cross-bridge Cycle
120.6K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
120.6K
